References
- B. R. Groveman et al., “Sporadic Creutzfeldt-Jakob disease prion
infection of human cerebral organoids,” Acta Neuropathol. Commun.,
vol. 7, no. 1, pp. 1–12, 2019.
- A. Ladogana et al., “Mortality from Creutzfeldt–Jakob disease and
related disorders in Europe, Australia, and Canada,” Neurology, vol.
64, no. 9, pp. 1586–1591, 2005.
- S. J. Collins et al., “Determinants of diagnostic investigation
sensitivities across the clinical spectrum of sporadic
Creutzfeldt-Jakob disease,” Brain, vol. 129, no. 9, pp. 2278–2287,
2006, doi: 10.1093/brain/awl159.
- A. Krasnianski et al., “Neuropsychological symptoms in sporadic
Creutzfeldt-Jakob disease patients in Germany,” J. Alzheimer’s Dis.,
vol. 59, no. 1, pp. 329–337, 2017.
- [5] P. Brown, F. Cathala, P. Castaigne, and D. C. Gajdusek,
“Creutzfeldt‐Jakob disease: clinical analysis of a consecutive series
of 230 neuropathologically verified cases,” Ann. Neurol. Off. J. Am.
Neurol. Assoc. Child Neurol. Soc., vol. 20, no. 5, pp. 597–602, 1986.
- G. D. Rabinovici et al., “First symptom in sporadic
Creutzfeldt–Jakob disease,” Neurology, vol. 66, no. 2, pp. 286–287,
2006.
- G. S. Young et al., “Diffusion-weighted and fluid-attenuated
inversion recovery imaging in Creutzfeldt-Jakob disease: high
sensitivity and specificity for diagnosis,” Am. J. Neuroradiol., vol.
26, no. 6, pp. 1551–1562, 2005.
- J. N. Trollor, X. Chen, and P. S. Sachdev, “Neuroleptic malignant
syndrome associated with atypical antipsychotic drugs,” CNS Drugs,
vol. 23, no. 6, pp. 477–492, 2009.
- T. E. Bertorini, “Myoglobinuria, malignant hyperthermia, neuroleptic
malignant syndrome and serotonin syndrome,” Neurol. Clin., vol. 15,
no. 3, pp. 649–671, 1997.
- J. Latham, D. Campbell, and W. Nichols, “How much can exercise raise
creatine kinase level—and does it matter?,” Clin. Inq. 2008, 2008.
- R. J. Gurrera, “Sympathoadrenal hyperactivity and the etiology of
neuroleptic malignant syndrome,” Am. J. Psychiatry, vol. 156, no. 2,
pp. 169–180, 1999.
- Centers for disease control and prevention, “Diagnostic Criteria
| Creutzfeldt-Jakob Disease, Classic (CJD) | Prion
Disease | CDC,” 2018.
https://www.cdc.gov/prions/cjd/diagnostic-criteria.html (accessed Apr.
19, 2021).
- M. D. Geschwind, “Rapidly progressive dementia,” Contin. Lifelong
Learn. Neurol., vol. 22, no. 2 Dementia, p. 510, 2016.
- A. G. Osborn, G. L. Hedlund, and K. L. Salzman, Osborn’s Brain E-Book.
Elsevier Health Sciences, 2017.
- D. C. Fragoso et al., “Imaging of Creutzfeldt-Jakob disease: imaging
patterns and their differential diagnosis,” Radiographics, vol. 37,
no. 1, pp. 234–257, 2017.
- D. P. Seitz and S. S. Gill, “Neuroleptic malignant syndrome
complicating antipsychotic treatment of delirium or agitation in
medical and surgical patients: case reports and a review of the
literature,” Psychosomatics, vol. 50, no. 1, pp. 8–15, 2009.
- J. Mesquita and L. Siva, “Fatal neuroleptic malignant syndrome
induced by clozapine in Parkinson’s psychosis,” J. Neuropsychiatry
Clin. Neurosci., vol. 26, no. 1, pp. E34–E34, 2014.
- A. W. Lemstra, N. Schoenmaker, A. J. M. Rozemuller-Kwakkel, and W. A.
van Gool, “The association of neuroleptic sensitivity in Lewy body
disease with a false positive clinical diagnosis of Creutzfeldt-Jakob
disease,” Int. J. Geriatr. Psychiatry, vol. 21, no. 11, pp.
1031–1035, 2006, doi: 10.1002/gps.1602.
- J. Yang, H. Kuang, Q. Wang, J. Liu, X. Chen, and H. Shang, “Analysis
of Chinese patients with sporadic Creutzfeldt-Jakob disease,” Prion,
vol. 14, no. 1, pp. 137–142, 2020.
- D. N. Manners et al., “Pathologic correlates of diffusion MRI changes
in Creutzfeldt-Jakob disease,” Neurology, vol. 72, no. 16, pp.
1425–1431, 2009.
- C. Carswell et al., “MRI findings are often missed in the diagnosis
of Creutzfeldt-Jakob disease,” BMC Neurol., vol. 12, no. 1, pp. 1–5,
2012.
- M. Pocchiari et al., “Predictors of survival in sporadic
Creutzfeldt–Jakob disease and other human transmissible spongiform
encephalopathies,” Brain, vol. 127, no. 10, pp. 2348–2359, 2004.
- E. Nakatani et al., “Specific clinical signs and symptoms are
predictive of clinical course in sporadic Creutzfeldt− Jakob
disease,” Eur. J. Neurol., vol. 23, no. 9, pp. 1455–1462, 2016.
- F. Llorens et al., “A prognostic model for overall survival in
sporadic Creutzfeldt‐Jakob disease,” Alzheimer’s Dement., vol. 16,
no. 10, pp. 1438–1447, 2020.